Body Mass Index and Prognosis in Patients With Chronic Heart Failure: Insights From the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) Program

Background— In individuals without known cardiovascular disease, elevated body mass index (BMI) (weight/height2) is associated with an increased risk of death. However, in patients with certain specific chronic diseases, including heart failure, low BMI has been associated with increased mortality. Methods and Results— We examined the influence of BMI on prognosis using Cox proportional hazards models in 7599 patients (mean age, 65 years; 35% women) with symptomatic heart failure (New York Heart Association class II to IV) and a broad spectrum of left ventricular ejection fractions (mean, 39%) in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. During a median follow-up of 37.7 months, 1831 patients died. After adjustment for potential confounders, compared with patients with BMI between 30 and 34.9, patients in lower BMI categories had a graded increase in the risk of death. The hazard ratios (95% confidence intervals) were 1.22 (1.06 to 1.41), 1.46 (1.24 to 1.71), and 1.69 (1.43 to 2.01) among those with BMI of 25 to 29.9, 22.5 to 24.9, and <22.5, respectively. The increase in risk of death among patients with BMI ≥35 was not statistically significant (hazard ratio, 1.17; 95% confidence interval, 0.95 to 1.43). The association between BMI and mortality was not altered by age, smoking status, or left ventricular ejection fraction (P for interaction >0.20). However, lower BMI was associated with a greater risk of all-cause death in patients without edema but not in patients with edema (P for interaction <0.0001). Lower BMI was associated with a greater risk of cardiovascular death and noncardiovascular death. Baseline BMI did not influence the risk of hospitalization for worsening heart failure or due to all causes. Conclusions— In patients with symptomatic heart failure and either reduced or preserved left ventricular systolic function, underweight or low BMI was associated with increased mortality, primarily in patients without evidence of fluid overload (edema).

[1]  Kamyar Kalantar-Zadeh,et al.  Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. , 2004, Journal of the American College of Cardiology.

[2]  D. Levy,et al.  Survival After the Onset of Congestive Heart Failure in Framingham Heart Study Subjects , 1993, Circulation.

[3]  S. Shaughnessy,et al.  Do No Harm: Health Systems’ Duty to Promote Clinician Well-Being , 2022, American Journal of Hospital Medicine.

[4]  A Hofman,et al.  The prognosis of heart failure in the general population: The Rotterdam Study. , 2001, European heart journal.

[5]  Ronald M. Krauss,et al.  American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease , 1998 .

[6]  C. Lavie,et al.  Body composition and prognosis in chronic systolic heart failure: the obesity paradox. , 2002, The American journal of cardiology.

[7]  R. D'Agostino,et al.  Variability of body weight and health outcomes in the Framingham population. , 1991, The New England journal of medicine.

[8]  S. Anker,et al.  Tumor necrosis factor and steroid metabolism in chronic heart failure: possible relation to muscle wasting. , 1997, Journal of the American College of Cardiology.

[9]  P. Whelton,et al.  Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. , 2001, Archives of internal medicine.

[10]  M. Weber,et al.  Contrasting clinical properties and exercise responses in obese and lean hypertensive patients. , 2001, Journal of the American College of Cardiology.

[11]  G. Jennings,et al.  Regional sympathetic nervous activity and oxygen consumption in obese normotensive human subjects. , 1997, Circulation.

[12]  S. Coppack,et al.  Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. , 1999, American journal of physiology. Endocrinology and metabolism.

[13]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[14]  C. Lavie,et al.  Obesity, weight reduction and survival in heart failure. , 2002, Journal of the American College of Cardiology.

[15]  L. Wilhelmsen,et al.  Heart failure in the general population of men--morbidity, risk factors and prognosis. , 2001, Journal of internal medicine.

[16]  M. Pfeffer,et al.  Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. , 1999, Journal of cardiac failure.

[17]  C. Lambert,et al.  Effect of weight loss on left ventricular diastolic filling in morbid obesity. , 1995, The American journal of cardiology.

[18]  D. Levy,et al.  The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. , 1991, JAMA.

[19]  V. Froelicher,et al.  The prognostic value of body mass index and standard exercise testing in male veterans with congestive heart failure. , 2002, Journal of cardiac failure.

[20]  R. Vasan,et al.  Impact of obesity on the risk of heart failure and survival after the onset of heart failure. , 2004, The Medical clinics of North America.

[21]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[22]  Y. Guisez,et al.  Leptin Is an Endogenous Protective Protein against the Toxicity Exerted by Tumor Necrosis Factor , 1999, The Journal of experimental medicine.

[23]  M. Thun,et al.  Body-mass index and mortality in a prospective cohort of U.S. adults. , 1999, The New England journal of medicine.

[24]  L. Køber,et al.  Effect of obesity and being overweight on long-term mortality in congestive heart failure: influence of left ventricular systolic function. , 2005, European heart journal.

[25]  H. Krumholz,et al.  The obesity paradox: body mass index and outcomes in patients with heart failure. , 2005, Archives of internal medicine.

[26]  C. Lavie,et al.  Obesity and heart failure prognosis: paradox or reverse epidemiology? , 2005, European heart journal.

[27]  D. Levy,et al.  Obesity and the risk of heart failure. , 2003, The New England journal of medicine.

[28]  F. Alla,et al.  Differential clinical prognostic classifications in dilated and ischemic advanced heart failure: the EPICAL study. , 2000, American heart journal.

[29]  C. Berry,et al.  Catabolism in chronic heart failure. , 2000, European heart journal.

[30]  Abdissa Negassa,et al.  Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study , 2003, The Lancet.

[31]  M. Evans,et al.  Body weight and mortality among women. , 1997, Canadian family physician Medecin de famille canadien.

[32]  E. Frohlich,et al.  Obesity and suppressed B-type natriuretic peptide levels in heart failure. , 2004, Journal of the American College of Cardiology.

[33]  Claude Bouchard,et al.  Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. , 1998, WMJ : official publication of the State Medical Society of Wisconsin.

[34]  M. Cohen,et al.  Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. , 1997, The American journal of cardiology.

[35]  M. Pfeffer,et al.  Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme , 2003, The Lancet.

[36]  Christianna S. Williams,et al.  Risk factors for heart failure in the elderly: a prospective community-based study. , 1999, The American journal of medicine.

[37]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[38]  Andrew J S Coats,et al.  Body mass and survival in patients with chronic heart failure without cachexia: the importance of obesity. , 2003, Journal of cardiac failure.

[39]  S. Anker,et al.  Insights into the pathogenesis of chronic heart failure: immune activation and cachexia. , 1999, Current opinion in cardiology.

[40]  G. Fonarow,et al.  The relationship between obesity and mortality in patients with heart failure. , 2001, Journal of the American College of Cardiology.